Kevan R Polkinghorne1,2, Rory Wolfe1, Kim M Jachno1, James B Wetmore3,4, Robyn L Woods1, John J McNeil1, Mark R Nelson5, Christopher M Reid1,6, Anne M Murray3. 1. Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia. 2. Department of Nephrology, Monash Medical Centre, Monash Health, Melbourne, Victoria, Australia. 3. Department of Medicine, Hennepin Healthcare Systems, Minneapolis, Minnesota, USA. 4. Hennepin Healthcare Research Institute, Minneapolis, Minnesota, USA. 5. Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia. 6. School of Public Health, Curtin University, Perth, Western Australia, Australia.
Abstract
AIM: The prevalence of chronic kidney disease (CKD) in the elderly is controversial because age-related decline in kidney function may not truly reflect underlying kidney disease. We estimate the baseline prevalence and predictors of CKD using the CKD Epidemiology Collaboration (CKD-EPIeGFR ) and Berlin Initiative Study 1 (BIS1eGFR ) eGFR equations in the ASPirin in Reducing Events in the Elderly (ASPREE) trial cohort of healthy older participants. METHODS:GFR was estimated using CKD-EPI and BIS1 equations. CKD was defined as eGFR <60 mL/min/1.73 m2 or ≥ 60 mL/min/1.73 m2 with urine albumin creatinine ratio (UACR) ≥ 3 mg/mmol. Logistic regression was used to identify predictors of CKD prevalence defined by each eGFR equation. RESULTS: Data for analysis were complete for 17,762 participants. Mean age was 75.1 years (SD 5); 56.4% were female, 76.4% had hypertension, 9% had diabetes mellitus. Mean CKD-EPIeGFR was 73.0 (SD 14.2), compared with mean BIS1eGFR of 62.7 (11.4). Median UACR was 0.8 (IQR 0.5, 1.5) mg/mmol. Prevalence of CKD by CKD-EPIeGFR was 27% (predominantly due to normoalbuminuric stage 3a CKD), substantially lower than 47.1% by BIS1eGFR ; the difference was predominantly driven by reclassification of individuals from G1 and G2 CKD to stage G3a without albuminuria. Increased prevalence of CKD by either equation was related to older age, hypertension, diabetes, or higher body mass index. CONCLUSIONS: Prevalence of CKD with CKD-EPIeGFR was 27%, and doubled using the elderly specific BIS1eGFR , with most participants reclassified from stage 2 to stage 3a. Increased prevalence of CKD was related older age, hypertension, diabetes, or increased body mass index.
RCT Entities:
AIM: The prevalence of chronic kidney disease (CKD) in the elderly is controversial because age-related decline in kidney function may not truly reflect underlying kidney disease. We estimate the baseline prevalence and predictors of CKD using the CKD Epidemiology Collaboration (CKD-EPIeGFR ) and Berlin Initiative Study 1 (BIS1eGFR ) eGFR equations in the ASPirin in Reducing Events in the Elderly (ASPREE) trial cohort of healthy older participants. METHODS:GFR was estimated using CKD-EPI and BIS1 equations. CKD was defined as eGFR <60 mL/min/1.73 m2 or ≥ 60 mL/min/1.73 m2 with urine albumin creatinine ratio (UACR) ≥ 3 mg/mmol. Logistic regression was used to identify predictors of CKD prevalence defined by each eGFR equation. RESULTS: Data for analysis were complete for 17,762 participants. Mean age was 75.1 years (SD 5); 56.4% were female, 76.4% had hypertension, 9% had diabetes mellitus. Mean CKD-EPIeGFR was 73.0 (SD 14.2), compared with mean BIS1eGFR of 62.7 (11.4). Median UACR was 0.8 (IQR 0.5, 1.5) mg/mmol. Prevalence of CKD by CKD-EPIeGFR was 27% (predominantly due to normoalbuminuric stage 3a CKD), substantially lower than 47.1% by BIS1eGFR ; the difference was predominantly driven by reclassification of individuals from G1 and G2 CKD to stage G3a without albuminuria. Increased prevalence of CKD by either equation was related to older age, hypertension, diabetes, or higher body mass index. CONCLUSIONS: Prevalence of CKD with CKD-EPIeGFR was 27%, and doubled using the elderly specific BIS1eGFR , with most participants reclassified from stage 2 to stage 3a. Increased prevalence of CKD was related older age, hypertension, diabetes, or increased body mass index.
Authors: Daniel Murphy; Charles E McCulloch; Feng Lin; Tanushree Banerjee; Jennifer L Bragg-Gresham; Mark S Eberhardt; Hal Morgenstern; Meda E Pavkov; Rajiv Saran; Neil R Powe; Chi-Yuan Hsu Journal: Ann Intern Med Date: 2016-08-02 Impact factor: 25.391
Authors: Walter K Kremers; Aleksandar Denic; John C Lieske; Mariam P Alexander; Vidhu Kaushik; Hisham E Elsherbiny; Harini A Chakkera; Emilio D Poggio; Andrew D Rule Journal: Nephrol Dial Transplant Date: 2015-04-16 Impact factor: 5.992
Authors: John J McNeil; Rory Wolfe; Robyn L Woods; Andrew M Tonkin; Geoffrey A Donnan; Mark R Nelson; Christopher M Reid; Jessica E Lockery; Brenda Kirpach; Elsdon Storey; Raj C Shah; Jeff D Williamson; Karen L Margolis; Michael E Ernst; Walter P Abhayaratna; Nigel Stocks; Sharyn M Fitzgerald; Suzanne G Orchard; Ruth E Trevaks; Lawrence J Beilin; Colin I Johnston; Joanne Ryan; Barbara Radziszewska; Michael Jelinek; Mobin Malik; Charles B Eaton; Donna Brauer; Geoff Cloud; Erica M Wood; Suzanne E Mahady; Suzanne Satterfield; Richard Grimm; Anne M Murray Journal: N Engl J Med Date: 2018-09-16 Impact factor: 91.245
Authors: John J McNeil; Mark R Nelson; Robyn L Woods; Jessica E Lockery; Rory Wolfe; Christopher M Reid; Brenda Kirpach; Raj C Shah; Diane G Ives; Elsdon Storey; Joanne Ryan; Andrew M Tonkin; Anne B Newman; Jeff D Williamson; Karen L Margolis; Michael E Ernst; Walter P Abhayaratna; Nigel Stocks; Sharyn M Fitzgerald; Suzanne G Orchard; Ruth E Trevaks; Lawrence J Beilin; Geoffrey A Donnan; Peter Gibbs; Colin I Johnston; Barbara Radziszewska; Richard Grimm; Anne M Murray Journal: N Engl J Med Date: 2018-09-16 Impact factor: 91.245
Authors: Stein I Hallan; Kunihiro Matsushita; Yingying Sang; Bakhtawar K Mahmoodi; Corri Black; Areef Ishani; Nanne Kleefstra; David Naimark; Paul Roderick; Marcello Tonelli; Jack F M Wetzels; Brad C Astor; Ron T Gansevoort; Adeera Levin; Chi-Pang Wen; Josef Coresh Journal: JAMA Date: 2012-12-12 Impact factor: 56.272
Authors: Rory Wolfe; James B Wetmore; Robyn L Woods; John J McNeil; Hugh Gallagher; Paul Roderick; Rowan Walker; Mark R Nelson; Christopher M Reid; Raj C Shah; Michael E Ernst; Jessica E Lockery; Andrew M Tonkin; Walter P Abhayaratna; Peter Gibbs; Erica M Wood; Suzanne E Mahady; Jeff D Williamson; Geoffrey A Donnan; Geoffrey C Cloud; Anne M Murray; Kevan R Polkinghorne Journal: Kidney Int Date: 2020-09-10 Impact factor: 10.612
Authors: Jennifer A Hirst; José M Ordóñez Mena; Chris A O'Callaghan; Emma Ogburn; Clare J Taylor; Yaling Yang; F D Richard Hobbs Journal: PLoS One Date: 2021-01-15 Impact factor: 3.240
Authors: Suzanne E Mahady; Karen L Margolis; Andrew Chan; Galina Polekhina; Robyn L Woods; Rory Wolfe; Mark R Nelson; Jessica E Lockery; Erica M Wood; Christopher Reid; Michael E Ernst; Anne Murray; Ltp Thao; John J McNeil Journal: Gut Date: 2020-08-03 Impact factor: 31.793
Authors: Liubov D Robman; Le Thi Phuong Thao; Robyn H Guymer; Rory Wolfe; Robyn L Woods; Lauren Ab Hodgson; James Phung; Galina A Makeyeva; Y-Anh Le-Pham; Suzanne G Orchard; Jewhara Suleiman; Emily Maguire; Ruth E Trevaks; Stephanie A Ward; Moeen Riaz; Paul Lacaze; Elsdon Storey; Walter P Abhayaratna; Mark R Nelson; Michael E Ernst; Christopher M Reid; John J McNeil Journal: Contemp Clin Trials Commun Date: 2020-10-11